Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

At the heart of Eli Lilly's recent success and future prospects lies its formidable GLP-1 portfolio, headlined by Mounjaro (tirzepatide) and Zepbound. These drugs have shown remarkable efficacy in ...

At the heart of Eli Lilly's recent success and future prospects lies its formidable GLP-1 portfolio, headlined by Mounjaro (tirzepatide) and Zepbound. These drugs have shown remarkable efficacy in ...

Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of ...

The names at the forefront of weight loss drugs are Eli Lilly, the U.S. manufacturer of Mounjaro and Zepbound; and Novo Nordisk, the Danish maker of Ozempic, Saxenda, and Wegovy. However ...

Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

At the heart of Eli Lilly's growth story is its robust portfolio of GLP-1 drugs. Mounjaro and Zepbound have shown impressive prescription growth trends, with Mounjaro experiencing a 21.6% ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity. Revenue gains ...